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ot is my distinct pleasure to welcome you into fellowship in
he American College of Cardiology (ACC). You have
chieved an important career milestone, an honor that will
ring you respect and admiration from your colleagues,
atients, and society. However, it is also an achievement
hat brings great responsibility and ethical burdens that will
emand constant vigilance.
The initials F.A.C.C. are something money cannot buy.
hey stand for high ideals. As Fellows of the ACC, we owe
great debt to those ideals. The precise nature of that debt
s a matter of history and circumstance.
Our obligation is clear: We need to remove the biases that
tand in the way of good medicine and sound research. We
eed to assure that no consideration of economic self-
nterest will ever prevent us from giving our patients the
afest, most effective, and most economically responsible
ealth care possible.
Health care is expensive. It is a Hummer-sized piece of
he economy. During your lifetime, it will probably exceed
full one-fourth of the gross national product (1). One
eason it is so expensive is because it works. Cardiac care has
ed the way in extending our life span and, more impor-
antly, improving the quality of life. But the returns may be
iminishing.
For example, the obesity-diabetes epidemic is upon us.
his epidemic is literally fed by our fast-food culture. It is
ndemic among the poor, who are also the most likely to
moke and least likely to have health care insurance.
We debate about how to handle the uninsured poor. We
re a democracy. We tolerate many points of view, but we
hould not tolerate death by poverty. We all know hyper-
ension is highly treatable with drugs. It is not treatable,
owever, if you do not have $100 a month to spend on
ntihypertensive drugs.
Many pharmaceutical companies have commendable pro-
rams to help the poor (2), but it is a patchwork effort.
here is no substitute for a systematic solution that involves
ll sectors of the health care economy.
We need a better government safety net. We are wealthy
nd aspire to be a humanistic culture. Posterity will measure
ur character by how we treat the weakest and most
ulnerable among us. No one should have to choose
etween food and health care. oWe are looking at an avalanche of heart disease in the
oming years. It is linked to another issue about which I feel
trongly: racial disparity in disease outcomes.
In 2000, the death rate from heart disease was almost
0% greater among African-American adults than Cauca-
ians. Death rates from stroke were 40% higher (3). Our
esearch priorities should be aligned to address the stagger-
ng disparity. We need to amplify our emphasis on preven-
ion and screening for this population.
Government is moving slowly on these issues. I recently
poke to an exiled physician from the Ninth Ward in New
rleans. He said that nearly 50% of his practice was unable
o pay him. This dedicated doctor is doing more than his
hare. But who should be responsible for solving this
roblem—a few extraordinary individuals willing to make
reat personal sacrifices for health care equality, or a wealthy
ociety that more uniformly spreads the burden?
So, here are the pivotal questions. What role should the
CC play in this debate? Should our advocacy efforts focus
olely on protecting our economic self-interest, or should we
pply some of our intellectual and financial capital to the
ational discussion of these formidable problems?
As cardiologists we are part of the problem, but we are
lso part of the solution.
Can we do more with less? Technology is playing havoc
ith health costs. We pay more because we can do more. In
he case of new imaging technologies, we pay more because
e can see more. Is what we see worth looking at?
New imaging modalities provide a clearer picture of the
eart and vascular system than ever before. But what may be
seful and beneficial is still evolving. Our infatuation with
echnology can be wonderful, but it is costly and must be
sed appropriately.
I share the enthusiasm for emerging technologies like
ardiac computed tomography. At the same time, our
nthusiasm must be tempered by judgment. The history of
edicine is replete with examples of new technologies that
ave been rushed into practice without the evidence needed
o use them wisely.
How do we answer the question of appropriate use? The
ollege has begun development of guidelines for appropri-
te use (4). These guidelines represent the collective wisdom
f our specialty. We will do well to consult them in making
ur clinical choices.
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eed to prepare for them. The first step is to look to our
rofessional integrity.
Trust is priceless equity. It defines the relationship
etween the doctor and the patient. It can be protected and
urtured and passed on to future generations. Or it can be
quandered.
I am concerned that our public trust is endangered. We
re too entangled with pharmaceutical suppliers. We need
o take additional steps to secure our integrity. In health
are, where so much is at stake, even the appearance of bias
an damage trust as much as actual impropriety.
Just as our country is addicted to oil, our profession is
ddicted to the financial support of drug and device man-
facturers.
Please do not misunderstand me. The most important
dvances in medical practice have come from the willingness
f industry to invest billions of dollars in new medicines and
nnovative cardiovascular devices. Without industry, there
ould be no statin drugs, no drug-eluting stents, and no
mplantable cardioverter-defibrillators.
The philanthropy of our industry partners has helped us
chieve many of the most important accomplishments of
ur College. But this system has become out of balance.
Industry is now the dominant source of funding for
edical education (5–7). In most hospitals, grand rounds
nd educational seminars are almost exclusively funded by
ndustry. Our professional journals rely on advertising to pay
he bills, and our national meetings are partially funded by
assive industry exhibitions.
The College currently works diligently to meet—or
xceed—accepted best practices to make certain that this
unding does not come with strings attached (8,9). We need
he strongest possible firewalls between the educational
ontent of our programs and the sources of funding.
The College is leading the way in identifying and
ontaining these potential conflicts, but we must never let
ur guard down.
There is nothing more valuable than our scientific integ-
ity. The most important evidence used to support our
ractice guidelines arises from clinical trials. With the
urrent focus of the National Institutes of Health on basic
esearch, contemporary clinical trials are now almost exclu-
ively funded by industry. There are so many of them that
e are running out of acronyms.
Some industry-funded trials are independently directed
y academic investigators, but most are not. An entirely new
ndustry has sprouted during the past 25 years—contract
esearch organizations. These for-profit research companies
re well-equipped to run large clinical trials on behalf of
harmaceutical or device companies.
Unfortunately, however, they are accountable only to the
ponsor, not the physician-scientists who enroll patients in
linical trials, nor to the patients who volunteer to participate.
This trend threatens the integrity of the most important
ource of evidence used to advance medical practice. The iesign of trials administered by non-academic organizations
ay subtly or not-so-subtly favor the therapy being inves-
igated.
If results are unfavorable, the results are simply not
ublished, a phenomenon known as negative publication
ias. The failure to publish negative results has an unques-
ionably harmful effect on medical science. We are unwit-
ingly barred from learning from these failed experiments
nd, therefore, are likely to repeat such failures.
Regrettably, I must also tell you that some of the most
mportant clinical trial manuscripts are ghost-written by
ommunications companies, not the investigators. Agreeing
o serve as an author of such a study is a betrayal of
rofessional and public trust. Without academic authors
illing to accept such practices, ghost-writing would not be
ossible.
I am currently leading a large clinical trial financed by a
ajor drug company. No representative of the company sits
n the executive committee. No academic participant may
ccept honoraria, speaking fees, or other compensation from
ny manufacturer of drugs in this class. At the trial’s
onclusion, we intend to provide the study database to the
ational Heart, Lung, and Blood Institute so that indepen-
ent investigators can explore the results. This will not only
e one of the largest clinical trials ever conducted, but one
f the most transparent.
Several academic research groups are leading the way to
mprove the research environment. Particularly notable are
he Duke Clinical Research Institute and the Thrombolysis
n Myocardial Infarction Group at the Brigham and Wom-
n’s Hospital in Boston. Similar to the Cleveland Clinic
ardiovascular Coordinating Center, these fine research
nstitutes require unrestricted access to the trial database and
nlimited rights to publish the results.
Several leading journals have also taken up the integrity
ssue, most notably our own Journal of the American College
f Cardiology and Journal of the American Medical Association
JAMA), which require statistical confirmation of clinical
rial results by external academic sources for all industry-
ponsored studies (10).
Individual practitioners also must share responsibility.
e should be pleased to participate in industry-sponsored
linical trials, but the investigators must control the trial
ata and be completely free to publish it when and where
hey want. This may cost us some personal opportunities,
ut it is worth it. Our integrity has no price.
Big trials receive public scrutiny, but professional societies
re private affairs. Clinical practice guidelines are developed
y committees behind closed doors. Our guidelines should
epresent the mean of evidence, experience, and judgment of
he most qualified specialists in their field. They need to be
orged in the crucible of science, not commerce.
In 2002, a JAMA study examined committees that estab-
ished guidelines endorsed for common adult diseases. It
ound that 80% of authors of guidelines had some form of
nteraction with the pharmaceutical industry (11).
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May 2, 2006:1901–3 President’s PageI do not for a moment suggest that the guidelines of the
CC reflect commercial bias, but we need to assure that
hey never will. Or never even appear to. How can this be
ccomplished? The first step is to make it clear that we are
ware of the potential for bias or conflict of interest.
The ACC, again, is leading the way in establishing the
ighest principles of integrity and transparency in matters of
rofessional ethics. As individuals, we also need to draw
lear lines around the pharmaceutical industry relationship
12,13).
I offer you my personal solution. I donate any drug-
ndustry consulting fees offered to me to a philanthropic
harity run by the College. No income, no tax deduction.
lease consider this course of action for yourselves. You will
leep better at night, and your favorite charity will be
rateful for the support.
As president, I will solicit opinions on these critical
atters. It is my hope that we can reach a consensus that
eflects the pure love of science and medicine that is the
allmark of our organization.
We are a privileged group. With that privilege, comes
reat responsibility. I have fought for justice and equality all
y life. If there is an elite out there, I am usually against it,
ut the ACC represents an elite in the very best sense of the
ord.
You are the shining faces of our profession. You are the
dvocates, speakers, volunteers, researchers, teachers, pre-
enters, authors, healers, and leaders. You are the operators,
urgeons, practitioners, and clinicians that all others look to
or example.
I urge you to use your great skills with common human-
ty, and share them with every patient, regardless of life
tatus.
You have joined a great network of ACC fellows. We are
ere to help you with information and experience. The
ollege will be your partner throughout your career, to
upport your practice, and to challenge you to be the best
ardiologist you can be.I welcome you to fellowship in this best of all elites, and
ish you the most rewarding and fulfilling careers.
ddress correspondence to: Dr. Steven E. Nissen, American
ollege of Cardiology, c/o Cathy Lora, 9111 Old Georgetown
oad, Bethesda, Maryland 20814-1699.
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